Y
Yervoy
Productby Bristol Myers Squibb
Heard in 2 episodes across 2 shows since Oct 2026
Yervoy is the brand name for ipilimumab, an immune checkpoint inhibitor targeting CTLA-4 and used in several cancer treatments.
Episodes
2
across 2 shows
First heard
Oct 2026
Expert statements
1
1 positive
Episodes per month
Public PodLume episodes featuring it, over the last year.
2
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 2 |
| Nov 2026 | 0 |
Email alert
Email me when Yervoy comes up on a podcast
One email a week at most, with the new episodes that mention Yervoy. Free, no account needed, unsubscribe in one click.
What experts have said about Yervoy
1 statement · 1 positive
BMS’s neoadjuvant Opdualag/Yervoy approach outperformed Moderna’s trial results.
“when you do that, the results are actually a lot better than the Moderna trial would be”
Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Listen at 11:10
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Yervoy, newest first
